1. Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study
- Author
-
Salvatore D’Angelo, Enrico Tirri, Angela Maria Giardino, Marco Mattucci-Cerinic, Lorenzo Dagna, Leonardo Santo, Francesco Ciccia, Bruno Frediani, Marcello Govoni, Francesca Bobbio Pallavicini, Rosa Daniela Grembiale, Andrea Delle Sedie, Rita Mulè, Francesco Paolo Cantatore, Rosario Foti, Elisa Gremese, Paola Conigliaro, Fausto Salaffi, Ombretta Viapiana, Alberto Cauli, Roberto Giacomelli, Luisa Arcarese, Giuliana Guggino, Romualdo Russo, Amy Puenpatom, Domenico Capocotta, Francesca Nacci, Maria Grazia Anelli, Valentina Picerno, Corrado Binetti, Florenzo Iannone, D'Angelo, Salvatore, Tirri, Enrico, Giardino, Angela Maria, Mattucci-Cerinic, Marco, Dagna, Lorenzo, Santo, Leonardo, Ciccia, Francesco, Frediani, Bruno, Govoni, Marcello, Bobbio Pallavicini, Francesca, Grembiale, Rosa Daniela, Delle Sedie, Andrea, Mulè, Rita, Cantatore, Francesco Paolo, Foti, Rosario, Gremese, Elisa, Conigliaro, Paola, Salaffi, Fausto, Viapiana, Ombretta, Cauli, Alberto, Giacomelli, Roberto, Arcarese, Luisa, Guggino, Giuliana, Russo, Romualdo, Puenpatom, Amy, Capocotta, Domenico, Nacci, Francesca, Anelli, Maria Grazia, Picerno, Valentina, Binetti, Corrado, and Iannone, Florenzo
- Subjects
rheumatoid arthritis ,anti-TNF inhibitor ,psoriatic arthriti ,axial spondyloarthriti ,golimumab ,biologic ,psoriatic arthritis ,axial spondyloarthritis ,General Medicine - Abstract
In this prospective observational study, data were collected from 34 rheumatology clinics in Italy in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) who started golimumab (GLM) as a second anti-TNFα drug. The primary objective was to evaluate the effectiveness of GLM after 6 months. Changes in quality of life using the EQ-5D-5L were also assessed. A total of 194 patients aged 53.2 ± 12 years started GLM as a second anti-TNF drug: 39 (20.1%) with RA, 91 (46.9%) with PsA and 64 (32.9%) with axSpA. After 6 months of GLM treatment, 68% of RA patients achieved low disease activity (LDA; DAS28-CRP ≤ 3.2), 31.9% of PsA patients achieved minimal disease activity and 32.5% of axSpA patients achieved LDA (ASDAS-CRP < 2.1). Good/moderate EULAR response was achieved in 61.9% and 73.8% of patients with RA and PsA, respectively, and 16% of axSpA patients achieved a 50% improvement in BASDAI. Across all indications, improvements in disease activity measures and EQ-5D-5L domains were observed over 6 months. The main reasons for GLM interruption were lack/loss of efficacy (7.2%) or adverse events (2%). This study confirms the effectiveness of GLM as a second-line anti-TNF for the treatment of RA, PsA and axSpA in a real-world setting in Italy.
- Published
- 2022